Overview

General Prognostics (GPx) develops clinically validated digital biomarkers that transform consumer wearables into continuous biomarker monitoring platforms. Our CardioID software detects early physiologic changes associated with heart failure deterioration. Operating at the intersection of digital health and cardiovascular medicine, GPx plans its first FDA submission in Q2 2026.